Author

Stuart Spencer

Observed names: S K M Spencer, S. Spencer, Spencer Stuart, Stuart K. Spencer

Observed institutions: AstraZeneca (United Kingdom), Fox Chase Cancer Center, Harvard University, Johns Hopkins University, University of Oxford, Dana-Farber Cancer Institute

OpenAlex ID: A5111855870

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 · Jonathan Ledermann, Philipp Harter, et al. · The Lancet Oncology · 1,437

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

2016 · Jonathan A Ledermann, Philipp Harter, et al. · The Lancet Oncology · 448

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes

2018 · Darren R. Hodgson, Brian A. Dougherty, et al. · British Journal of Cancer · 233

PDF

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

2018 · Michael Friedlander, Ursula Matulonis, et al. · British Journal of Cancer · 186

PDF

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

2013 · Caroline Robert, Reinhard Dummer, et al. · The Lancet Oncology · 167

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

2017 · Brian A. Dougherty, Zhongwu Lai, et al. · Oncotarget · 96

PDF

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

2016 · Ursula A. Matulonis, Philipp Harter, et al. · Cancer · 92

PDF

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer

2016 · Jonathan A Ledermann, Philipp Harter, et al. · British Journal of Cancer · 58

PDF

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

2022 · Yuanbin Chen, Luis Paz-Ares, et al. · JTO Clinical and Research Reports · 50

PDF

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research

2022 · Dipak Kotecha, Folkert W Asselbergs, et al. · European Heart Journal · 37

PDF

Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303)

2007 · H. J. Wanebo, M. Ghebremichael, et al. · Journal of Clinical Oncology · 37

LBA86 Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN

2020 · J.W. Goldman, M.C. Garassino, et al. · Annals of Oncology · 32

PDF

Lessons from the PURE study

2014 · Stuart Spencer · Global Cardiology Science and Practice · 32

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy

2013 · S K M Spencer, A J C Pommier, et al. · British Journal of Cancer · 30

PDF

Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I Study

2013 · Jair Bar, Stuart Spencer, et al. · Clinical Colorectal Cancer · 28

A global perspective on hypertension: a Lancet Commission

2015 · Michael Hecht Olsen, Stuart Spencer · The Lancet · 23

Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer

2014 · Jonathan Ledermann, Philipp Harter, et al. · Obstetrical & Gynecological Survey · 19

Global Burden of Disease 2010 Study: A personal reflection

2013 · Stuart Spencer · Global Cardiology Science and Practice · 17

MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN

2021 · M.C. Garassino, Y. Shrestha, et al. · Journal of Thoracic Oncology · 16

Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).

2010 · H. J. Wanebo, M. S. Ghebremichael, et al. · Journal of Clinical Oncology · 16

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

2018 · Ruth Plummer, Henk M. Verheul, et al. · Advances in Therapy · 15

Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges

2023 · Faiez Zannad, Filippo Crea, et al. · European Heart Journal · 14

PDF

Early predictions of response and survival from a tumor dynamics model in patients with recurrent, metastatic head and neck squamous cell carcinoma treated with immunotherapy

2021 · Ignacio González‐García, Vadryn Pierre, et al. · CPT Pharmacometrics & Systems Pharmacology · 14

PDF

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

2014 · A J C Pommier, R Shaw, et al. · British Journal of Cancer · 14

Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.

2016 · Jonathan A. Ledermann, Philipp Harter, et al. · Journal of Clinical Oncology · 12

Works count: 76

Citation count: 3,192

H-index: 17

I10-index: 26